In light of the COVID-19 emergency, Radetec Diagnostics has decided to apply its optimised quantum dots – LFA technology for the detection of SARS-CoV-2 antigens in nasopharyngeal swab specimens collected from the respiratory mucosa or saliva sample. Radetec’s test will detect the virus in the early stages of infection, allowing for rapid diagnosis and decision support in the treatment and spread prevention of COVID-19.
Radetec’s COVID-19 rapid test is an in-vitro diagnostic (IVD) Class III medical device intended to be used by trained clinicians for point-of-care screening of (but not limited to):
- Densely-populated areas, such as airplanes, cruise ships or concerts
- Businesses far from clinics such as mines, offshore platforms and remote operations.